info@cellmed.in

The Science of Regenerative Capabilities

Stem Cells possess unique potential to transform into specialized cells forming cartilage, bone, blood, nerves, tendon, muscle tissue, and more. Recent studies reveal stem cells regenerative capabilities, elevating its status as a potential, modern treatment to counteract cell deterioration caused by age, disease, injury, or congenital defects.

Stem Cells Application in Veterinary Care

  • Stem cell therapy has emerged as a groundbreaking innovation in veterinary care. In the realm of canine health, ongoing stem cells research supported by scientific publications exhibits unparalleled regenerative potential, promoting cartilage regeneration, tissue repair anti-inflammatory properties. The innovative approach extends with age related degeneration its benefits to address orthopedic issues, skin conditions, optic health, nerve damage, and chronic organ-related problems in dogs.

Positive Outcome

  • Currently there are limited treatment options available for the conditions shortlisted for treatment with stem cells.
  • Stem cell treatment addresses the root cause of the condition through the process of regeneration and thereby improving the quality of life of the pet.
  • Sufficient scientific studies are in the public domain as supporting evidence for stem cell therapeutic application.

Type of Stem Cells

  • Mesenchymal stem cells (MSCs) are widely favored in stem cell therapy for their remarkable attributes.
  • MSCs exert trophic, immunosuppressive, anti-inflammatory and anti- apoptotic effects and activate the body's own stem cells, modulating the local environment & thereby stimulating tissue regeneration.
  • In canine scientific studies, the use of MSCs sourced from Adipose Tissue and Bone Marrow is prevalent. The popularity of adipose tissue-derived MSCs (AD-MSCs) can be attributed to quality, quantity, potency and easy accessibility. It is seen that these stem cells help repair damaged cartilage and bone tissue, decrease inflammation and pain, heal damaged cells, prevent further cell deterioration, promote active tissue regeneration and improve animals’ overall health.
Types of stem cells

Source of Stem Cells

  • The tissue cultured for the MSCs can be collected from patient's own tissue (Autologous), a healthy donor of the same species (Allogeneic) or a species other than that of the patient (Xgenogenic).

Allogeneic Stem Cell Therapy

  • To attain allogeneic stem cells there is no invasive procedure required for the treatment of the injured animal. The adipose tissue cells are taken from another, young and healthy donor animal of the same species. The quality of the animals owns stem cells are dependent on the health and age of the animal drastically affecting the capability to perform.

Benefits Include

  • "Ready to Treat," offering a practical alternative to time-consuming autologous procedures.
  • Do not need donor-host compatibility for matching.
  • Offer the benefit of being healthy, robust and exhibiting enhanced potency capabilities.
  • Administered safely in both humans and animals with no significant adverse effects.
  • Cost Effective.

Global Presence

  • Regenerative medicine has garnered substantial attention in veterinary care, emerging as a viable alternative to traditional approaches such as surgery, medication, and rehabilitation. Notably, the market for regenerative therapies is prominently led by small animals, with canine & feline taking center stage in its widespread adoption and success.
  • The Canine Stem Cell Therapy global market, valued at US$173.1 Million in 2022 with the US holding a 30% share, is anticipated to expand to US$228.1 Million by 2030. This growth, at a CAGR of 3.5% during the analysis period from 2022 to 2030, highlights the sector's steady progression.
  • Japan and Canada are notable geographic markets poised for growth, forecasted at 3.3% and 2.9%, respectively, over the 2022-2030 period. In Europe, Germany is expected to exhibit a robust 3.4% CAGR.
  • Specifically, Allogeneic Canine Stem Cells are projected to achieve a 4% CAGR, reaching US$157.6 Million by the conclusion of the analysis period.
Orthopedic Conditions Treatment

© CellMed Biotech Pvt. Ltd